CERO Company Profile and Key Details

CERO has shown weak momentum, losing -95.24% over the past week and -98.76% over the past quarter, though year-to-date performance is down -99.92%. Short-term trend indicators are bullishly aligned (SMA20 -96.73%, SMA50 -98.04%, SMA200 -99.37%). The stock’s 14-day RSI is 12.27 (weak momentum), while the ATR of 0.44 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.99% below its high and over 11.88% above its low. Average 10-day trading volume of 524.72 thousand shares is below the 3-month average of 908.43 thousand, indicating normal recent market interest.

CERo Therapeutics Holdings, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.45. This means the shares are trading below this model’s fair value.

CERo Therapeutics Holdings, Inc. has 1.21 million shares outstanding. The public float is 1.10 million shares, elevated short interest at 3.23% of float. This equals 38.01 thousand shares. The short ratio is 1.0 days. Institutional investors hold 0.15% of the float. Insiders own 4.13%.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $30.00. The high target offers 299900.0% upside. The low target suggests 299900.0% downside. The mean target is $30.00. This offers 299900.0% upside. CERo Therapeutics Holdings, Inc. earnings surprise history is a mixed track record. The quarter that ended May 15, 2026, missed forecasts by -75.01%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -73.32% in May 15, 2025.

The stock is currently mid-range between its 52-week high and low $0.01 and $8.90. With a market capitalization of about $12.05 thousand, CERo Therapeutics Holdings, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.16). Key stats such as the average daily volume over the past year has been around 898.43 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, CERo Therapeutics Holdings, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Ehrlich, the company employs approximately 8 people and listed since November 30, 2021. CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers.

CERo Therapeutics Holdings, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.04 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.0, also above market averages.

Our AI price prediction model suggests that CERo Therapeutics Holdings, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -16.67%, with price expected at $0.01 by August 04, 2026, within a range of $0.01 to $0.01 3-Month Outlook: Projected rise of 400.0%, reaching $0.06 by October 19, 2026, with a range of $0.00 to $2.80. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 21, 2027, within a range of $0.00 to $126.09.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) shares are down -99.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CERo Therapeutics Holdings, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $30.00, suggesting 249900.0% upside. Our AI forecast model points to short-term weakness (-16.67% over two weeks), a medium-term rise (400.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.